More info
Active ingredients
Dexamethasone + Neomycin + Polymyxin B
Release form
Drops
Composition
Dexamethasone 1 mg, neomycin 3.5 mg, polymyxin B sulfate 6 thousand. IU
Pharmacological effect
Combined drug for local use in ophthalmology. Neomycin has a bactericidal effect, disrupting the synthesis of the protein of a bacterial cell. It is active against Staphylococcus aureus, Corynebacterium diphteriae, Streptococcus viridans, Escherichia coli, Klepsiella pneumoniae, Proteus vulgaris, Aerobacter aerogenes, Haemophillus influenzae. Active against Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Klersiella pneumoniae, Koch-Weeks bacillus. Dexamethasone. It has anti-inflammatory, anti-allergic and desensitizing effects. It has antiexudative effect. Dexamethasone effectively suppresses inflammatory processes. The combination of GCS with antibiotics reduces the risk of developing an infectious process.
Pharmacokinetics
When applied topically, systemic absorption is low.
Indications
Infections of the eye and its appendages: - blepharitis; - conjunctivitis; - keratoconjunctivitis; - keratitis; - iridocyclitis. Prevention of postoperative infectious complications.
Contraindications
- individual hypersensitivity to the components of the drug; - viral eye diseases (including keratitis caused by Herpes simplex, chicken pox); - mycobacterial eye infection; - eye tuberculosis; - acute shingles; - fungal eye diseases; - condition after removal of a corneal foreign body; - purulent infection of the mucous membrane of the eye and eyelids, caused by microorganisms resistant to the action of neomycin, purulent corneal ulcer.
Precautionary measures
Do not exceed the recommended dose. With caution prescribed for glaucoma, cataracts.
Use during pregnancy and lactation
Sufficient experience in the use of the drug during pregnancy and lactation is not. It is possible to use for the treatment of pregnant women as prescribed by the attending physician, if the expected therapeutic effect exceeds the risk of possible side effects. It is necessary to interrupt the use of the drug for the period of breastfeeding.
Dosage and administration
Locally. With a mild infectious process, 1-2 drops to the conjunctival sac 4-6 times / day. In acute severe infectious process, 1-2 drops to the conjunctival sac every 60 minutes with a decrease in the frequency of instillations of the drug as the inflammation decreases.
Side effects
LocalAllergic reaction, accompanied by itching and swelling of the eyelids, conjunctival hyperemia. Side effects caused by the steroid component: increased intraocular pressure with possible subsequent development of glaucoma, damage to the optic nerve and visual fields (using the drug for more than 10 days requires monitoring of intraocular pressure); rear subcapsular cataract, slowing the healing process of wounds. Topical use of steroids for diseases that cause thinning of the cornea or sclera, can lead to their perforation. Secondary infection. The development of a secondary infection is observed after the use of combined drugs containing GCS in combination with antibiotics. With prolonged use of steroids may develop fungal infections of the cornea. The appearance of non-healing ulcers on the cornea after long-term treatment with steroid preparations may indicate the development of fungal invasion. Secondary bacterial infection may occur as a result of suppression of the protective reaction of the patient.
Overdose
During the use of eye drops, Maxitrol cases of overdose are not specified.
Interaction with other drugs
Interaction with other drugs is currently not known. In case of use with other local ophthalmologic drugs, the interval between their use should be at least 10 minutes.
special instructions
The bottle must be closed after each use. Shake the bottle before use.